Chemed (NYSE:CHE) EVP Spencer Lee Sells 1,000 Shares of Stock

Key Points

• Chemed EVP Spencer Lee sold 1,000 shares at an average price of $541.04, generating $541,040 and reducing his direct stake by 6.71% to 13,912 shares.
• Chemed reported quarterly adjusted earnings of $6.06 per share and revenue of $673.25 million, beating analyst expectations; revenue increased 8.8% year over year. The company issued fiscal 2026 EPS guidance of $25.00–$25.75.
• The company raised its quarterly dividend to $0.70 per share, or $2.80 annually, while analysts maintained a consensus “Hold” rating with an average price target of $530.75.

Chemed Corporation (NYSE:CHE - Get Free Report) EVP Spencer Lee sold 1,000 shares of Chemed stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the sale, the executive vice president directly owned 13,912 shares of the company's stock, valued at approximately $7,526,948.48. This trade represents a 6.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Chemed Stock Performance

Shares of CHE stock traded up $0.95 during mid-day trading on Monday, reaching $541.52. 21,011 shares of the company's stock traded hands, compared to its average volume of 215,475. The firm has a 50 day moving average price of $499.24 and a two-hundred day moving average price of $446.50. The firm has a market capitalization of $7.08 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.05 and a beta of 0.51. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $557.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91.

Chemed (NYSE:CHE - Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.46. The company had revenue of $673.25 million during the quarter, compared to analysts' expectations of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. Chemed's quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the company posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, research analysts forecast that Chemed Corporation will post 23.18 EPS for the current year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Monday, August 17th. This is a positive change from Chemed's previous quarterly dividend of $0.60. Chemed's dividend payout ratio (DPR) is currently 14.06%.

Wall Street Analyst Weigh In

CHE has been the subject of several recent analyst reports. Weiss Ratings raised Chemed from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 17th. Oppenheimer boosted their price objective on Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Zacks Research raised Chemed from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Finally, Royal Bank Of Canada increased their price target on Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a research report on Thursday, July 30th. One research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $530.75.

Institutional Investors Weigh In On Chemed

A number of hedge funds have recently bought and sold shares of the company. Geneos Wealth Management Inc. raised its stake in shares of Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock valued at $61,000 after purchasing an additional 76 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Chemed by 67.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company's stock valued at $5,534,000 after acquiring an additional 4,560 shares during the period. Marshall Wace LLP acquired a new stake in shares of Chemed in the 2nd quarter valued at $579,000. Brown Advisory Inc. boosted its stake in shares of Chemed by 36.9% in the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company's stock valued at $267,000 after purchasing an additional 148 shares in the last quarter. Finally, Cerity Partners LLC grew its holdings in shares of Chemed by 237.7% in the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company's stock worth $2,165,000 after purchasing an additional 3,133 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source